Financial report
The consolidated financial statements include the financial statements of the Company and the subsidiaries listed below. Details of investments in subsidiaries as at 30 June are as follows:
|
|
|
|
|
|
Name |
Location |
Percentage of ownership |
|
|
|
|
|
|
|
|
|
30 June 2021 |
31 December 2020 |
|
PolyPeptide Laboratories Holding B.V. |
Hoofddorp, The Netherlands |
100% |
100% |
|
PolyPeptide Laboratories Holding (PPL) AB |
Malmö, Sweden |
100% |
100% |
|
PolyPeptide S.A. |
Braine, Belgium |
100% |
100% |
|
PolyPeptide Laboratories (Sweden) AB |
Malmö, Sweden |
100% |
100% |
|
PolyPeptide Laboratories A/S |
Hillerød, Denmark |
100% |
100% |
|
PolyPeptide Institute Spol S.r.o. |
Prague, Czech Republic |
0% |
100% |
|
PolyPeptide Laboratories GmbH |
Wolfenbüttel, Germany |
100% |
100% |
|
PolyPeptide Laboratories Inc. |
Torrance, USA |
100% |
100% |
|
PolyPeptide Laboratories San Diego LLC |
San Diego, U.S.A. |
100% |
100% |
|
PolyPeptide Labs Pvt Ltd |
Mumbai, India |
100% |
100% |
|
PolyPeptide Laboratories France SAS |
Strasbourg, France |
100% |
100% |
Percentage of voting shares is equal to percentage of ownership.
PolyPeptide Institute Spol S.r.o. has been liquidated during the first six months of 2021 and PolyPeptide Laboratories GmbH is in the process of liquidation. No further financial impact is expected related to the final liquidation of this company.